Colorectal cancer survival at an oncologic center in Colombia. A historic cohort study

Campo-Sánchez, S.M.; Camargo-Trillos, J.; Calle-Ramírez, J.A.; Gómez-Wolff, L.R.; Sánchez-Patiño, L.A.; García-García, Héctor Iván

doi:10.1016/j.rgmxen.2018.07.001

Cited by 6 publications

(4 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Colorectal cancer (CRC), as one of the highly malignant cancers with a poor prognosis, leads to a large number of deaths worldwide, and millions of people get CRC every year. 1, 2 CRC mostly affects the rectum, the sigmoid colon and the distal part of the descending colon. 3 Colorectal tumorigenesis begins with a progressive transformation of epithelial cells.…”

Section: Introductionmentioning

confidence: 99%

MiR‐4319 suppresses colorectal cancer progression by targeting ABTB1

Huang

Zhang

et al. 2019

UEG Journal

View full text Add to dashboard Cite

Background Colorectal cancer is one of the highly malignant cancers with a poor prognosis. The exact mechanism of colorectal cancer progression is not completely known. Recently, microRNAs (miRNAs, miRs) were suggested to participate in the regulation of multiple cancer development, including colorectal cancer. Methods MiR-4319 expression in colorectal cancer patient samples was detected by real-time polymerase chain reaction. MiR-4319 was knocked down in the colorectal cancer cells by siRNA transfection to study the role of miR-4319 in the cell cycle and proliferation of colorectal cancer cells. Results MiR-4319 expression was found to be inverse correlated with survival in colorectal cancer patients. Overexpression of miR-4319 markedly reduced the proliferation of colorectal cancer cells and altered cell cycle distribution. A further experiment showed that ABTB1 is the target gene of miR-4319. MiR-4319 was regulated by PLZF. Conclusion Our studies indicated that reduced expression of miR-4319 was correlated with poor prognosis in colorectal cancer patients; miR-4319 also suppressed colorectal cancer cell proliferation by targeting ABTB1. ABTB1 might become an excellent therapeutic target for colorectal cancer treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

MiR‐4319 suppresses colorectal cancer progression by targeting ABTB1

Huang

Zhang

et al. 2019

UEG Journal

View full text Add to dashboard Cite

show abstract

“…11 On the other hand, when comparing data from Latin America, 195 patients with metastatic CRC from Colombia reported an OS of 27% at 24 months. 12 As can be seen from these data, there is a marked difference between developed and developing countries. Thus, it is crucial to clarify why the OS presented in this study is higher than the data presented in the reference studies.…”

Section: Discussionmentioning

confidence: 92%

Colorectal Cancer Screening in Araba (Basque Country)

Iturralde-Iriso,

Orcajo-Bermúdez,

Guinea-Castañares

et al. 2023

Cancer Screen Prev

View full text Add to dashboard Cite

Background and objectives: Colorectal cancer (CRC) ranks third in incidence and second in mortality worldwide. In Ecuador, there are 2,481 new CRC cases per year and 2,366 cancer deaths yearly. CRC presents in stages III-IV in more than 50% of patients. The standard treatment for CRC is chemotherapy, with an overall survival (OS) of 29-31 months. The status of biomarkers KRAS, NRAS, BRAF, and MSI provides prognostic and predictive value. This study aimed to determine OS and progression-free survival (PFS) for metastatic CRC based on these molecular markers with a minimum follow-up of one year. Methods:This was an observational longitudinal analytical study at the Hospital de Especialidades Eugenio Espejo (HEEE). We obtained demographic, anatomopathological-molecular, and clinical data from the medical records of patients with metastatic CRC from July 1, 2018 until December 31, 2020.Results: Data were collected from a total of 177 patients. The median follow-up was 21.6 months. The median PFS was 15 months (11.6-18.3) in those with mutated (MT) markers, 18 months (15.7-20.2) for wild type (WT), and 9 months (4.1-13.8) for not performed markers (NR), with a hazard ratio (HR) for PFS in MT versus WT of 0.76; the 95% confidence interval (CI) (0.4-1.4) with p = 0.4. for OS was 21 months (17.1-24.8) for MT markers,[22][23][24][25][26]2) for WT markers, and 19 months (17.7-20.2) for NR. There were no significant differences in OS for MT vs. WT: HR = 1.38, 95% CI (0.8-2.3) p = 0.6. There was no significant association between OS or PSF and KRAS, NRAS, BRAF, and MSI mutations. KRAS was the most mutated marker, with a frequency of 40.2%. Conclusions:In the first monocentric study of mutations in metastatic CRC patients from Ecuador, patients with WT molecular markers reached the most prolonged OS and PFS, and KRAS had the highest mutation frequency. However, further studies with larger sample sizes are required to corroborate our findings.

show abstract

“…Con base en un estudio clínico previo de nuestra institución 29 , encontramos como el cáncer de recto pasó del 45 % entre 2011 y 2015, a ser más frecuente que el cáncer de colon en la serie actual, con el 55 %.…”

Section: Discussionunclassified

Determinación de los factores predictivos para complicaciones en cirugía electiva de pacientes con cáncer colorrectal. Experiencia del Instituto de Cancerología Las Américas Auna (Colombia, 2016-2019)

et al. 2021

View full text Add to dashboard Cite

Introducción. El pilar fundamental del tratamiento del cáncer colorrectal es la cirugía, situación que expone a los pacientes a la posible presentación de complicaciones, morbimortalidad, pobre calidad de vida, recurrencia tumoral o la muerte. El objetivo de este estudio fue determinar las variables clínicas y quirúrgicas que inciden en el riesgo de la aparición de complicaciones en los pacientes con cáncer colorrectal llevados a cirugía electiva entre los años 2016 y 2019. Métodos. Estudio observacional, descriptivo, transversal y retrospectivo. Se incluyeron pacientes mayores de 18 años con cáncer colorrectal sometidos a cirugía electiva. Se realizó un análisis multivariado para determinar los factores que se relacionan con las complicaciones postquirúrgicas. Resultados. Se incluyeron 298 pacientes, 68 % mayores de 60 años, 52,3 % mujeres, 74,2 % presentaban comorbilidades y 48,3 % fueron diagnosticados en estadio III. El 48,3 % presentó complicaciones postoperatorias. De ellos, el 68,1 % no tenía tamización nutricional y el 61,8 % no tenía preparación del colon; un 55 % fueron cirugías del recto, 69,1 % de las cirugías fueron por vía laparoscópica y 71,8 % presentaron sangrado inferior a 500 ml. La mayoría de las complicaciones fueron clasificadas como Clavien-Dindo I-III. Discusión. Las características de los pacientes fueron similares a los presentados en otros estudios, aunque hubo mayor incidencia de íleo postoperatorio. El análisis multivariado mostró una mayor probabilidad de presentar una complicación en pacientes con diabetes mellitus, hipertensión arterial, falta de tamización nutricional o preparación de colon, cirugía de recto y el sangrado mayor a 500 ml.

show abstract

Colorectal cancer survival at an oncologic center in Colombia. A historic cohort study

Cited by 6 publications

References 49 publications

MiR‐4319 suppresses colorectal cancer progression by targeting ABTB1

MiR‐4319 suppresses colorectal cancer progression by targeting ABTB1

Colorectal Cancer Screening in Araba (Basque Country)

Determinación de los factores predictivos para complicaciones en cirugía electiva de pacientes con cáncer colorrectal. Experiencia del Instituto de Cancerología Las Américas Auna (Colombia, 2016-2019)

Contact Info

Product

Resources

About